Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vusolimogene Oderparepvec and Pembrolizumab in Advanced Angiosarcoma
NCT06898970Phase 2Recruiting
- Start
- Jan 2026
- Primary completion
- Oct 2029
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vusolimogene oderparepvec in angiosarcoma. Primary endpoints: Percentage of participants with reported treatment-emergent adverse events (Safety Lead-In) at 1 year, Proportion of participants who experience an objective response at 1 year and 1 more. Started Jan 2026; status: recruiting.
02
Drugs
vusolimogene oderparepvec
03
Conditions
angiosarcoma
Beyond the preview
Go deeper on NCT06898970.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06898970.